SequelSEC

GT Biopharma, Inc. GTBP

Pharmaceutical Preparations · CIK 0000109657 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2021-09-30
Operating income
-$41.53M
Fiscal year ended 2021-09-30
Free cash flow
Unavailable
Fiscal year ended 2021-09-30

Valuation, from the filing

Public float$8.60MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.27Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio0.16x7th

GT Biopharma, Inc. (GTBP) reported revenue of $0 and net income of -$46.28M for the fiscal year ended 2021-09-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from GT Biopharma, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

GT Biopharma, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-09-30
Revenue$0
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$41.53M
Net income-$46.28M
Research & development$3.52M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrative$38.01M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

GT Biopharma, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-09-30
Cash & equivalentsUnavailable
Total assetsUnavailable
Current assets$35.80M
Total liabilitiesUnavailable
Current liabilities$3.92M
Total equity incl. NCI$31.88M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$2.80M

Cash flow

GT Biopharma, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-09-30
Operating cash flow-$13.83M
Capital expendituresUnavailable
Investing cash flowUnavailable
Financing cash flow$49.19M
Net change in cash$9.33M
Stock-based compensation$11.05M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

GT Biopharma, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-09-30
Free cash flowUnavailable
Gross marginUnavailable
Operating marginUnavailable
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio9.13x
Revenue YoY growthUnavailable
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open GTBP in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-Q/A · Filed 2026-03-06View SEC filing
10-Q/A · Filed 2026-03-06View SEC filing
10-K · Filed 2026-03-02View SEC filing
10-Q · Filed 2025-11-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.